Tags

Type your tag names separated by a space and hit enter

LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Curr Med Res Opin 2005; 21(11):1865-74CM

Abstract

BACKGROUND

The ratio of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (LDL-C/HDL-C) is a reliable predictor of cardiovascular risk. Low HDL-C levels in patients with coronary artery disease are associated with a high risk for cardiovascular events.

OBJECTIVES

This study compared the effects of rosuvastatin and atorvastatin on the LDL-C/HDL-C.

METHODS

Patients aged 40-80 years with established cardiovascular disease and HDL-C < 1.0 mmol/L (< 40 mg/dL) entered as a 6-week dietary run-in period, before randomisation to open-label treatment with rosuvastatin 10 mg (n = 230) or atorvastatin 20 mg (n = 231) for 6 weeks. Doses were increased after 6 weeks to rosuvastatin 20 mg or atorvastatin 40 mg, and after 12 weeks to rosuvastatin 40 mg or atorvastatin 80 mg. Serum lipid parameters were measured at baseline and 6, 12 and 18 weeks.

RESULTS

After 6 weeks of treatment, mean percentage change from baseline in LDL-C/HDL-C ratio was -47.0% in the rosuvastatin group and -41.9% in the atorvastatin group (p < 0.05 for between-group comparison). After 12 and 18 weeks of treatment, change from baseline was -53.0% and -57.3%, respectively, for rosucastatin, compared with -47.9% and -49.6%, respectively, for atorvastatin (p < 0.01 and p < 0.001, respectively, for between-group comparison). Rosuvastatin also reduced LDL-C, total cholesterol/HDL-C significantly more than atorvastatin at all three time points, and significantly improved total cholesterol/HDL-C and apolipoprotein B/A-I ratios.

CONCLUSIONS

Rosuvastatin 10, 20 and 40 mg is significantly more effective than atorvastatin 20, 40 and 80 mg, respectively, in improving the LDL-C/HDL-C ratio in patients with cardiovascular disease and low HDL-C. Further studies are required to clarify the benefits of rosuvastatin for reduction of cardiovascular risk.

Authors+Show Affiliations

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. j.w.jukema@lumc.nl

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16307708

Citation

Jukema, J Wouter, et al. "LDL-C/HDL-C Ratio in Subjects With Cardiovascular Disease and a Low HDL-C: Results of the RADAR (Rosuvastatin and Atorvastatin in Different Dosages and Reverse Cholesterol Transport) Study." Current Medical Research and Opinion, vol. 21, no. 11, 2005, pp. 1865-74.
Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin. 2005;21(11):1865-74.
Jukema, J. W., Liem, A. H., Dunselman, P. H., van der Sloot, J. A., Lok, D. J., & Zwinderman, A. H. (2005). LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current Medical Research and Opinion, 21(11), pp. 1865-74.
Jukema JW, et al. LDL-C/HDL-C Ratio in Subjects With Cardiovascular Disease and a Low HDL-C: Results of the RADAR (Rosuvastatin and Atorvastatin in Different Dosages and Reverse Cholesterol Transport) Study. Curr Med Res Opin. 2005;21(11):1865-74. PubMed PMID: 16307708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. AU - Jukema,J Wouter, AU - Liem,An-Ho, AU - Dunselman,Peter H J M, AU - van der Sloot,Jos A P, AU - Lok,Dirk J A, AU - Zwinderman,Aeilko H, PY - 2005/11/26/pubmed PY - 2006/2/14/medline PY - 2005/11/26/entrez SP - 1865 EP - 74 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 21 IS - 11 N2 - BACKGROUND: The ratio of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (LDL-C/HDL-C) is a reliable predictor of cardiovascular risk. Low HDL-C levels in patients with coronary artery disease are associated with a high risk for cardiovascular events. OBJECTIVES: This study compared the effects of rosuvastatin and atorvastatin on the LDL-C/HDL-C. METHODS: Patients aged 40-80 years with established cardiovascular disease and HDL-C < 1.0 mmol/L (< 40 mg/dL) entered as a 6-week dietary run-in period, before randomisation to open-label treatment with rosuvastatin 10 mg (n = 230) or atorvastatin 20 mg (n = 231) for 6 weeks. Doses were increased after 6 weeks to rosuvastatin 20 mg or atorvastatin 40 mg, and after 12 weeks to rosuvastatin 40 mg or atorvastatin 80 mg. Serum lipid parameters were measured at baseline and 6, 12 and 18 weeks. RESULTS: After 6 weeks of treatment, mean percentage change from baseline in LDL-C/HDL-C ratio was -47.0% in the rosuvastatin group and -41.9% in the atorvastatin group (p < 0.05 for between-group comparison). After 12 and 18 weeks of treatment, change from baseline was -53.0% and -57.3%, respectively, for rosucastatin, compared with -47.9% and -49.6%, respectively, for atorvastatin (p < 0.01 and p < 0.001, respectively, for between-group comparison). Rosuvastatin also reduced LDL-C, total cholesterol/HDL-C significantly more than atorvastatin at all three time points, and significantly improved total cholesterol/HDL-C and apolipoprotein B/A-I ratios. CONCLUSIONS: Rosuvastatin 10, 20 and 40 mg is significantly more effective than atorvastatin 20, 40 and 80 mg, respectively, in improving the LDL-C/HDL-C ratio in patients with cardiovascular disease and low HDL-C. Further studies are required to clarify the benefits of rosuvastatin for reduction of cardiovascular risk. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16307708/LDL_C/HDL_C_ratio_in_subjects_with_cardiovascular_disease_and_a_low_HDL_C:_results_of_the_RADAR__Rosuvastatin_and_Atorvastatin_in_different_Dosages_And_Reverse_cholesterol_transport__study_ L2 - http://www.tandfonline.com/doi/full/10.1185/030079905X74952 DB - PRIME DP - Unbound Medicine ER -